Skip to main content
    O

    Organogenesis Holdings Inc (ORGO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.80
    -0.01 (-0.86%)

    Market Cap: $105.15M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Organogenesis Holdings Inc (ORGO) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Organogenesis Holdings (ORGO) trades at 0.3x sales and 0.9x book value. Its P/S of 0.3x is below its 5-year median of 0.9x. Its forward P/E is 12.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E12.7x
    Price to sales0.3x
    Price to book0.9x
    PEGN/A
    FCF yield-0.1%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/EN/A21.3xN/A
    P/S0.3x0.9xN/A
    P/B0.9x1.6xN/A
    Medians of month-end values through Oct 2026: 52 to 60 months (5-year).

    Valuation History

    Over the 6 of the 9 year ends shown that have a P/E, its P/E ranged from 12.7x in 2021 to 57.9x in 2020.

    Year endPriceP/EP/SP/B
    2025$5.1817.9x1.2x1.6x
    2024$3.2016.3x0.9x1.1x
    2023$4.0954.0x1.2x1.9x
    2022$2.6915.0x0.8x1.3x
    2021$9.2412.7x2.6x5.1x
    2020$7.5357.9x2.4x6.4x
    2019$4.81N/A1.7x8.5x
    2018$10.15N/AN/A16.6x
    2017$9.92N/AN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About ORGO

    What is ORGO's forward P/E ratio?

    Organogenesis Holdings has a forward P/E ratio of 12.7x.

    What is ORGO's price to sales ratio?

    Organogenesis Holdings has a price to sales ratio of 0.3x.

    What is Organogenesis Holdings's average P/E ratio over 5 years?

    Organogenesis Holdings's median P/E over the last 5 years is 21.3x, from 52 month-end values through Oct 2026.